Clinical trial NCT03993353: Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
Official title: A Phase II Study of Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Conditions: Head and Neck Cancer
Head and Neck Squamous Cell Carcinoma
Head and Neck Carcinoma
Head and Neck Cancer Stage III
Head and Neck Cancer Stage IV
Head and Neck Cancer Metastatic
Cancer
Cancer of Esophagus
Cancer, Metastatic
Cancer of Head and Neck
Cancer of Mouth
Cancer of Neck
Keywords: cancer
pembrolizumab
tadalafil
cialis
opdivo
immunotherapy
metastatic
carcinoma
pd-1
pde
Lead sponsor: University of California, San Diego
Sponsor class: OTHER
First posted: 2019-06-20
Enrollment: 7
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study will examine the combination of pembrolizumab and tadalafil for safety and efficacy in advanced head and neck cancer.

Detailed description: Immune competent animal models of HNSCC demonstrate that combination PDE-5 inhibitor (tadalafil) and PD-1 inhibitor therapy is more effective than either therapy alone based on the concept of targeting multiple immune repressive abnormalities simultaneously (PD-1 checkpoint and myeloid suppressive pathways).

This trial will test the hypothesis that combination PD-1 inhibition and PDE-5 inhibition can be safely co-administered, and secondarily test the hypothesis that the combination of both therapies will be more effective than PD-1 inhibition alone in recurrent/metastatic HNSCC.

Eligibility criteria: Selected Inclusion Criteria:

* Patients (at least 18 years of age) must have recurrent or metastatic squamous cell carcinoma of the head and neck.
* Presence of measurable disease.
* Life expectancy of greater than 12 weeks
* Patients must have normal organ and marrow function

Selected Exclusion Criteria:

* Prior therapy with an PD-1 or PD-L1 inhibitor in the recurrent or metastatic setting
* Uncontrolled central nervous system metastases (stable metastases permitted)
* Active autoimmune disease
* Chemotherapy ≤28 days prior to first administration of study treatment and/or monoclonal antibody ≤8 weeks prior to first administration of study treatment.
* Prior daily use of tadalafil or other long-acting PDE5 inhibitors for one month or greater within 3 months of trial enrollment
* Current use of all other long-acting PDE5 inhibitors.
* Known severe hypersensitivity to tadalafil or any of the excipients of this product
* Current treatment with nitrates
* Current systemic treatment with a potent cytochrome P450 3A4 (CYP3A4) inhibitor such as ketoconazole or ritonavir.
* Current treatment with guanylate cyclase (GC) stimulators such as riociguat.
* History of hypotension and/or blindness and/or sensorineural hearing loss during prior treatment with tadalafil or other PDE-5 inhibitors
* History of known hereditary degenerative retinal disorders, including retinitis pigmentosa
* Prior history of non-arteritic anterior ischemic optic neuropathy
* Pregnant or breastfeeding; a negative pregnancy test is required within 14 days of randomization for all women of childbearing potential.
* History of stroke within prior 6 months.
* History of acute myocardial infarction within prior 3 months, uncontrolled angina, uncontrolled arrhythmia, or uncontrolled congestive heart failure
* Left ventricular outflow obstructions, such as aortic stenosis and idiopathic hypertrophic subaortic stenosis
* Angina requiring treatment with long-acting nitrates
* Angina requiring treatment with short-acting nitrates within 90 days of planned tadalafil administration
* Unstable angina within 90 days of visit 1 (Braunwald 1989)
* Positive cardiac stress test without documented evidence of subsequent, effective cardiac intervention
* History of any of the following coronary conditions within 90 days of planned tadalafil administration:

  * Myocardial Infarction
  * Coronary artery bypass graft surgery
  * Percutaneous coronary intervention (for example, angioplasty or stent placement)
  * Any evidence of heart disease (NYHA ≥ Class II as defined in Protocol Attachment LVHG.3) within 6 months of planned tadalafil administration
* Concurrent systemic immunosuppressant therapy (e.g., cyclosporine A, tacrolimus, etc., or chronic administration of \>10 mg/day of prednisone or equivalent)
* Prior organ transplantation
* Known history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV).

Primary outcomes:
measure: Rate of Dose Limiting Toxicity (DLT)
timeFrame: 2 years
measure: Overall Survival (OS)
timeFrame: 12 months
Secondary outcomes:
measure: Response measured by RECIST 1.1
timeFrame: 12 months
measure: Progression free survival
timeFrame: 2 years
measure: Adverse event rates
timeFrame: 2 years
Other outcomes:
Locations:
city: La Jolla
country: United States
facility: UCSD Moores Cancer Center
state: California
Study officials:
affiliation: UCSD
name: Joseph Califano
role: PRINCIPAL_INVESTIGATOR
References: